BRTX · BioRestorative Therapies, Inc.
$0.25
-0.02 (-7.31%)
At close · Jul 29
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on these conditions, we believe we do not have sufficient cash for at least twelve months after the issuance date of the financial statements included in this Quarterly Report which raises substantial doubt about our ability to continue as a going concern.”View the 10-Q filed May 14, 2026
Market Cap
$6.79M
Shares
25.48M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.25
Open$0.26
Day$0.23–0.28
52W$0.16–1.89
Avg vol 30d416K
Short int772K · 3.0% float · 2.6d
Short vol3%
Last earningsNov 12, 2025
DataJan 2020–Jul 2026
Filing10-Q · May 14
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 20.7 · elevated
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−64%
below
Price vs 50-day avg
−28%
below
RSI (14)
28
oversold
MACD trend
Negative
52-week position
5%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−34%
trailing
6-month return
−76%
trailing
YTD return
−79%
this year
Relative strength
−82%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
3 of 11 funds reported for Jun 30 · net +29.1K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.03% of float · ▼ -30.2% MoM · 2.6 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr low
11 holders — near 3-yr low, contrarian setup
Squeeze score
41
elevated · 0–100
Fundamentals
Revenue growth
+123%
Y/Y
Gross margin
415%
contracting
EPS growth
−36%
Y/Y
Free cash flow
$-10.9M
Buyback
$2.0M
remaining
Balance sheet
$1.3M
net cash
Quant / Vol
risk profile
Volatility
141%
annualized · 1-yr
Max drawdown
−91%
past year
ATR
14.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−64%
Bearish
Price vs 50-day avg
−28%
Bearish
RSI (14)
28
Neutral
MACD trend
Negative
Bearish
52-week position
5%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
3 of 11 funds reported for Jun 30 · net +29.1K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.03% of float · ▼ -30.2% MoM · 2.6 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr low
11 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
52-wk low $0
Now $0 · 5%
52-wk high $2
vs 200-day avg -64%
vs 50-day avg -28%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BRTX
this stock
BioRestorative Therapies, Inc.
|
$6.79M | -79.0% | +122.8% | — | 3.0% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +7.7% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.67B | +6.6% | +46.2% | 28.7 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.91B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +4.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BRTX | -22.1% | -34.3% | -76.0% | -34.3% | -79.0% |
| SPY | -2.4% | -2.3% | +6.3% | -2.3% | +7.0% |
| vs SPY | -19.7% | -32.0% | -82.3% | -32.0% | -85.9% |
Capital returns
Buyback program
· as of Mar 31, 2026
Authorized
$2.00M
Spent (derived)
$0
Remaining
$2.00M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.